"Celecoxib" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrazole derivative and selective CYCLOOXYGENASE 2 INHIBITOR that is used to treat symptoms associated with RHEUMATOID ARTHRITIS; OSTEOARTHRITIS and JUVENILE ARTHRITIS, as well as the management of ACUTE PAIN.
| Descriptor ID |
D000068579
|
| MeSH Number(s) |
D02.065.884.247 D02.886.590.700.247 D03.383.129.539.160
|
| Concept/Terms |
Celecoxib- Celecoxib
- 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide
SC 58635- SC 58635
- 58635, SC
- SC-58635
- SC58635
|
Below are MeSH descriptors whose meaning is more general than "Celecoxib".
Below are MeSH descriptors whose meaning is more specific than "Celecoxib".
This graph shows the total number of publications written about "Celecoxib" by people in this website by year, and whether "Celecoxib" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 13 | 13 |
| 2005 | 0 | 9 | 9 |
| 2006 | 0 | 10 | 10 |
| 2007 | 0 | 9 | 9 |
| 2008 | 0 | 7 | 7 |
| 2009 | 0 | 9 | 9 |
| 2010 | 0 | 8 | 8 |
| 2011 | 0 | 5 | 5 |
| 2012 | 0 | 7 | 7 |
| 2013 | 0 | 5 | 5 |
| 2014 | 0 | 2 | 2 |
| 2015 | 2 | 1 | 3 |
| 2016 | 2 | 2 | 4 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 5 | 6 |
| 2019 | 1 | 0 | 1 |
| 2020 | 3 | 0 | 3 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Celecoxib" by people in Profiles.
-
Opioid-Free Discharge After Pancreatic Resection Through a Learning Health System Paradigm. JAMA Surg. 2023 11 01; 158(11):e234154.
-
A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-na?ve first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms. Neuropsychopharmacology. 2024 Apr; 49(5):893-902.
-
Stabilization of E-cadherin adhesions by COX-2/GSK3? signaling is a targetable pathway in metastatic breast cancer. JCI Insight. 2023 03 22; 8(6).
-
Celecoxib Colorectal Bioavailability and Chemopreventive Response in Patients with Familial Adenomatous Polyposis. Cancer Prev Res (Phila). 2022 04 01; 15(4):217-223.
-
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. JAMA Oncol. 2021 Sep 01; 7(9):1291-1301.
-
Design and Synthesis of a Novel NIR Celecoxib-Based Fluorescent Probe for Cyclooxygenase-2 Targeted Bioimaging in Tumor Cells. Molecules. 2020 Sep 04; 25(18).
-
Biomarker Modulation Study of Celecoxib for Chemoprevention in Women at Increased Risk for Breast Cancer: A Phase II Pilot Study. Cancer Prev Res (Phila). 2020 09; 13(9):795-802.
-
Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial. Eur Respir J. 2020 05; 55(5).
-
Acute changes in colonic PGE2 levels as a biomarker of efficacy after treatment of the Pirc (F344/NTac-Apc?am1137) rat with celecoxib. Inflamm Res. 2020 Jan; 69(1):131-137.
-
Combination therapy with atorvastatin and celecoxib delays tumor formation in a Fanconi anemia mouse model. Pediatr Blood Cancer. 2019 01; 66(1):e27460.